Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

Published:2007-01 Issue:1 Volume:13 Page:38-45
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

ASTERMARK J.,ROCINO A.,VON DEPKA M.,VAN DEN BERG H. M.,GRINGERI A.,MANTOVANI L. G.,MORADO M.,GARRIDO R. P.,SCHIAVONI M.,VILLAR A.,WINDYGA J.,

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2006.01403.x/fullpdf

Reference39 articles.

1. The epidemiology of inhibitors in haemophilia A: a systematic review

2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

3. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

4. Immune tolerance: a synopsis of the international experience

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B;Thrombosis Research;2024-06

2. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice;Thrombosis and Haemostasis;2024-04-27

3. Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021;Research and Practice in Thrombosis and Haemostasis;2021-11-21

4. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort;Journal of Thrombosis and Haemostasis;2021-05-18

5. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor;International Journal of Hematology;2021-02-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3